ReviewJournal of cellular and molecular medicine2019
Insights into IL-29: Emerging role in inflammatory autoimmune diseases.
Review in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Serum profile of IL-29, IL-41, and raftlin in microvascular complications of type 2 diabetes mellitus.Scientific reports · 2026Article
- Skeletal muscle density mediates the relationships of monocyte-lymphocyte ratio, apolipoprotein A1/HDL, and alkaline phosphatase with thoracic aortic calcification: a multicenter study in patients undergoing maintenance dialysis.Lipids in health and disease · 2025Article
- Expression level and clinical significance of IL-29 in serum of patients with coronary heart disease.Journal of cardiothoracic surgery · 2025Article
- Exploring the Involvement of New Members of the Interleukin Family in Cardiovascular Disease.Current cardiology reviews · 2025Review
- Up and away with cervical cancer: IL-29 is a promising cytokine for immunotherapy of cervical cancer due to its powerful upregulation of p18, p27, and TRAILR1.Medical oncology (Northwood, London, England) · 2024Article
- Article
- Enamel Matrix Derivative Suppresses Chemokine Expression in Oral Epithelial Cells.International journal of molecular sciences · 2023Article
- Systematic levels of IL-29 and microRNA185-5p were not associated with severe COVID-19 in the Iranian population.Virology journal · 2023Article
- A Potential New Link Between Inflammation and Vascular Calcification.Journal of the American Heart Association · 2023Article
- Chronic Community Exposure to Environmental Metal Mixtures Is Associated with Selected Cytokines in the Navajo Birth Cohort Study (NBCS).International journal of environmental research and public health · 2022Article
- Review
- Interleukin-29 profiles in COVID-19 patients: Survival is associated with IL-29 levels.Health science reports · 2022Article
- Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications.Nature communications · 2022Article
- Psoriasis between Autoimmunity and Oxidative Stress: Changes Induced by Different Therapeutic Approaches.Oxidative medicine and cellular longevity · 2022Review
- The protective effects of Olmesartan against interleukin-29 (IL-29)-induced type 2 collagen degradation in human chondrocytes.Bioengineered · 2022Article
- Insights into IL-29: Emerging role in inflammatory autoimmune diseases.Journal of cellular and molecular medicine · 2019Review
- Enhanced serum interferon-lambda 1 interleukin-29 levels in patients with psoriasis vulgaris.Anais brasileiros de dermatologiaArticle
- Exploring Cytokine Networks in Resistant Hypertension.Nursing researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-29 (IL-29) is a newly discovered member of type III interferon. It mediates signal transduction via binding to its receptor complex and activates downstream signalling pathways, and therefore induces the generation of inflammatory components. Recent studies reported that expression of IL-29 is dysregulated in inflammatory autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, Sjögren's syndrome, psoriasis and systemic sclerosis. Furthermore, functional analysis revealed that IL-29 may involve in the pathogenesis of the inflammatory autoimmune disorders. In this review, we will systematically review the current knowledge about IL-29. The information collected revealed the regulatory role of IL-29 and may give important implications for its potential in clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.